(VIANEWS) – The Market ended the session with POXEL (POXEL.PA) rising 22.81% to €0.42 on Thursday while CAC 40 dropped 0.16% to €7,571.40.
POXEL’s last close was €0.34, 68.33% under its 52-week high of €1.08.
About POXEL
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, POXEL has a trailing twelve months EPS of €-1.08.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, POXEL’s stock is considered to be oversold (<=20).
Moving Average
POXEL’s worth is way higher than its 50-day moving average of €0.36 and way under its 200-day moving average of €0.56.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1050.6%, now sitting on 1.55M for the twelve trailing months.
More news about POXEL (POXEL.PA).
